Izvorni znanstveni članak
THE EFFECTS OF TRIMETAZIDINE ON QT-INTERVAL PROLONGATION IN PATIENTS WITH CHRONIC KIDNEY DISEASE STAGE III-IV (PREDIALYSIS CRD)
DIANA BALENOVIĆ
; Opća bolnica Sisak, Odjel za unutarnje bolesti, Sisak, Hrvatska
INGRID PRKAČIN
; Klinička bolnica Merkur i Medicinski fakultet Sveučilišta u Zagrebu, Zagreb, Hrvatska
GORDANA CAVRIĆ
; Klinička bolnica Merkur i Medicinski fakultet Sveučilišta u Zagrebu, Zagreb, Hrvatska
I. HORVAT
; Opća bolnica Sisak, Odjel za unutarnje bolesti, Sisak, Hrvatska
DARKO POČANIĆ
; Klinička bolnica Merkur i Medicinski fakultet Sveučilišta u Zagrebu, Zagreb, Hrvatska
I. BAOTIĆ
; Klinička bolnica Merkur i Medicinski fakultet Sveučilišta u Zagrebu, Zagreb, Hrvatska
Sažetak
Prolonged QT interval is a predictor of cardiovascular mortality. It indicates delayed repolarization of ventricular myocardium and is considered a precursor of malignant cardiac arrhythmias and sudden cardiac death. Increased cardiovascular risk (CVR) in the presence of prolonged QT interval, corrected by heart rate (QTc), is attributed to ventricular electrical instability. Patients with chronic renal disease (CRD) usually die from sudden cardiac death before reaching the inal stage, inal chronic kidney disease (CRD stage V). We investigated whether patients with CRD stage III-V have prolonged QT interval, what are the possible causes of this extension, and whether in this patient population trimetazidine application may affect the reduction in QT prolongation. Our study showed one quarter of predialysis patients, mostly asymptomatic, to have QT prolongation, thus being at a higher risk of CV events. Introducing trimetazidine along with standard therapy can reduce the incidence of sudden cardiac death, and calculation of the QTc index would be a useful and economical method of screening and monitoring high risk patients.
Ključne riječi
kidney disease; QT interval; sudden cardiac death; trimetazidine
Hrčak ID:
97324
URI
Datum izdavanja:
14.2.2013.
Posjeta: 2.311 *